Amgen sued the board in March 2024, after it declared Enbrel unaffordable for Colorado patients. The drugmaker argued not only that the board’s decision was wrong, but that the law setting up ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Sandoz's Erelzi has become the first biosimilar of Amgen's Enbrel (etanercept) blockbuster inflammatory diseases drug to gain FDA approval. Erelzi (etanercept-szzs) has been approved in all uses ...

The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...